|
WO2011060112A1
|
|
Deuterated tyrosine kinase inhibitors
|
|
WO2011014726A1
|
|
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
|
TW201100441A
|
|
Amino pyrimidine anticancer compounds
|
|
WO2009143051A1
|
|
Substituted imidazopyr-and imidazotri-azines
|
|
KR20110017845A
|
|
Mtor inhibitor salt forms
|
|
EP2271941A2
|
|
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
TW200944201A
|
|
Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridines
|
|
EP2265270A1
|
|
2-aminopyridine kinase inhibitors
|
|
WO2009091939A1
|
|
Imidazopyrazinol derivatives for the treatment of cancers
|
|
CN101998865A
|
|
Combined treatment with an EGFR kinase inhibitor and an inhibitor of C-KIT
|
|
AU2008307579A1
|
|
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
AU2008307634A1
|
|
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2178563A2
|
|
Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
|
|
EP2134860A1
|
|
Biological markers predictive of anti-cancer response to kinase inhibitors
|
|
WO2008128050A2
|
|
Methods for identification of modulators of carm1 methyl transferase activity
|
|
TW200900070A
|
|
Combination cancer therapy
|
|
AU2007203344A1
|
|
Isothiazole derivatives useful as anticancer agents
|
|
WO2008076143A1
|
|
Combination of igfr inhibitor and anti-cancer agent
|
|
WO2007117507A1
|
|
A method for the assay of rock kinase activity in cells
|
|
US2007280928A1
|
|
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
|
